重磅!首批通过一致性评价品种名单出炉,华海药业是很大赢家

2017-12-29 佚名 CFDA

12月29日,CFDA官网公布了第一批通过一致性评价的品种名单,首批通过一致性评价的共有17个品规药品,涉及11个药品,7个企业。其中,华海药业是最大赢家。

根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗器械审评审批制度的意见》(国发〔2015〕44号)、《国务院办公厅关于开展仿制药质量和疗效一致性评价的意见》(国办发〔2016〕8号)、《关于仿制药质量和疗效一致性评价工作有关事项的公告》(国家食品药品监督管理总局公告2017年第100号)的规定,经审查,现发布符合仿制药质量和疗效一致性评价要求的药品申请品种目录(见附件),上述品种的说明书、企业研究报告及生物等效性试验数据信息可登录国家食品药品监督管理总局药品审评中心网站(www.cde.org.cn)查询。

特此公告。

附件:2017年12月份已批准通过仿制药质量和疗效一致性评价品种目录

国家食品药品监督管理总局

2017年12月28日


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906857, encodeId=1c51190685e10, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed May 02 00:27:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274030, encodeId=9b9d2e403028, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 31 07:13:38 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444314, encodeId=802514443143a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549253, encodeId=33ec1549253c6, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-05-02 zhanfl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906857, encodeId=1c51190685e10, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed May 02 00:27:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274030, encodeId=9b9d2e403028, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 31 07:13:38 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444314, encodeId=802514443143a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549253, encodeId=33ec1549253c6, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 大爰

    学习并分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1906857, encodeId=1c51190685e10, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed May 02 00:27:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274030, encodeId=9b9d2e403028, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 31 07:13:38 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444314, encodeId=802514443143a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549253, encodeId=33ec1549253c6, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906857, encodeId=1c51190685e10, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed May 02 00:27:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274030, encodeId=9b9d2e403028, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 31 07:13:38 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444314, encodeId=802514443143a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549253, encodeId=33ec1549253c6, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Dec 31 04:27:00 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 xxxx1054

相关资讯

国家药品审评中心发布药物非临床安全性研究技术指导原则

      作为药审中心承担的十二五重大专项课题之法规科学的部分内容,2013年3月28日至29日,中心组织召开了药物非临床安全性研究技术指导原则合并修订/ 起草专题讨论会。会后药理毒理学部进行了深入讨论,现已经形成第二稿。按照工作计划,现公开征求意见,请广大药物研究相关人员提出意见和建议。     &

CDE终于发布《临床试验数据管理工作技术指南》(附下载)

CDE终于发布《临床试验数据管理工作技术指南》,临床试验数据管理的第一本指导性文件。足足有47页之多。涵盖了临床试验数据管理的全过程。标志着临床试验数据管理一个新时代的开启。附详细通知内容(转载自国家食品药品监督管理局药品审评中心): 临床试验数据是支持药品获准上市的最重要实证。良好规范的数据管理工作是保证临床试验质量的关键。我国《药品注册管理办法》和《药物临床试验质量管理规范》等对此均有相应的原

2014年3月CDE受理药品简介

2014年3月,CDE共受理药品申请745件,较2月份增长近40%。其中,新药申请212件,仿制申请193件,进口申请68件,均较2月份有不同程度的增加。 图2014年3月CDE受理药品申请类型分布 注册分类为1类的新药申报均为新药临床申请,共有16件,涉及7个品种,均为化学药品,其中有6个品种为1.1类,1个品种为1.6类。 除恒瑞医药所申报的SHR4640原料药及

2017年1类新药申请量或将突破200个

中国医药工业信息中心CPM数据库显示,截至2017年12月20日,CDE承办的1类化药数量达到199个,比2016年增长了42%。我国创新药研发用“爆发式增长”来形容的确一点都不为过。